PHIO PHARMACEUTICALS CORP.
257 Simarano Drive, Suite 101
Marlborough, MA 01752
May 5, 2023
VIA EDGAR
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama
| Re: | Phio Pharmaceuticals Corp. |
| Registration Statement on Form S-1 | |
| Filed April 28, 2023 | |
File No. 333-271521 | |
| Request for Acceleration of Effective Date |
Dear Ms. Gama:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on May 9, 2023, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Steven Abrams of Hogan Lovells US LLP at (267) 675-4671. Also, please notify Mr. Abrams when this request for acceleration has been granted.
| Very truly yours, | ||
| PHIO PHARMACEUTICALS CORP. | ||
| By: | /s/ Robert J. Bitterman | |
| Name: | Robert J. Bitterman | |
| Title: | President and Chief Executive Officer | |
